IP Verse

Medical Device And Method For Providing Information For Glycemic Control - EP3254616

The patent EP3254616 was granted to Sanofi Aventis Deutschland on Jun 9, 2021. The application was originally filed on Feb 3, 2010 under application number EP17182868A. The patent is currently recorded with a legal status of "Revoked".

EP3254616

SANOFI AVENTIS DEUTSCHLAND
Application Number
EP17182868A
Filing Date
Feb 3, 2010
Status
Revoked
Mar 3, 2023
Publication Date
Jun 9, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ROCHEFeb 23, 2022GRUNECKER PATENT -

Patent Citations (15) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONEP1281351
OPPOSITIONEP3254616
OPPOSITIONUS4731726
OPPOSITIONWO03005891
OPPOSITIONWO2006131345
OPPOSITIONWO2007000427
OPPOSITIONWO2008094249
OPPOSITIONWO2009001349
SEARCHUS2002107476
SEARCHUS2004122353
SEARCHUS2005277911
SEARCHUS2008126969
SEARCHUS2008172027
SEARCHUS2008319384
SEARCHWO03046695

Non-Patent Literature (NPL) Citations (15) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- H. YKI-JARVINEN et al., "Insulin glargine or NPH combined with metformin in type 2 diabetes: he LANMET Study", Diabetologica
DESCRIPTION- MELANIE DAVIES et al., "Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes", Diabetes Care, (20050600), vol. 28, no. 6, pages 1282 - 1288, XP055247721
DESCRIPTION- ROBERT J. HEINE et al., "Exenatide versus Insulin Glargine in Patients with Suboptimally Controlled Type 2 Diabetes, A Randomized Trial", Annals of Internal Medicine, (20051000), vol. 143, no. 8, pages 559 - 569
DESCRIPTION- ANTHONY BARNET, "Dosing of Insulin Glargine in the Treatment of Type 2 Diabetes", Clinical Therapeutics, (20070000), vol. 29, no. 6, doi:doi:10.1016/j.clinthera.2007.06.018, pages 987 - 999, XP022189297
DESCRIPTION- H.C. GERSTEIN et al., "A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas", Diabetic Medicine, (20060000), vol. 23, doi:doi:10.1111/j.1464-5491.2006.01881.x, pages 736 - 742, XP055023383
DESCRIPTION- POUL STRANGE, "Treat-to-Target Insulin Titration Algorithms When Initiating Long or Intermediate Acting Insulin in Type 2 Diabetes", Journal of Diabetes Science and Technology, (20070700), vol. 1, no. 4, doi:doi:10.1177/193229680700100412, pages 540 - 548, XP055307441
EXAMINATION- ON BEHALF OF THE AT LANTUS STUDY GROUP DAVIES ET AL, "Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies", DIABETES RESEARCH AND CLINICAL PRACTICE, AMSTERDAM, NL, (20071105), vol. 79, no. 2, ISSN 0168-8227, pages 368 - 375, XP022435424
EXAMINATION- SHAEFER ET AL, "Is diabetes mellitus ready for the ''Do It Yourself'' approach?", 20071001, (20071001), vol. 2, no. 4, pages 154 - 156, XP022358366
EXAMINATION- MENEGHINI L ET AL, "The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patientswith type 2 diabetes ? results of the randomized, controlled PREDICTIVETM 303 study", DIABETES, OBESITY AND METABOLISM, BLACKWELL SCIENCE, vol. 9, no. 6, doi:10.1111/J.1463-1326.2007.00804.X, ISSN 1462-8902, (20071101), pages 902 - 913, (20071007), XP007915817
OPPOSITION- Austenat Elke, "Das Insulinpumpen-Buch", Berlin Wien, Blackwell-Wiss.-Verlag, (19990101), pages 1 - 145, ISBN 978-3-89412-340-6, XP055897231
OPPOSITION- DAVID RODBARD et al., "A data management program to assist with home monitoring of blood glucose and self adjustment of insulin dosage for patients with diabetes mellitus and their physicians", Proc. Annu. Symp. Cumput. Appl Med. Care, (19841100), pages 321 - 324, XP055307442
OPPOSITION- SCHULZ et al., "Diabetes self-adjustment by a computerized program - first experiences in inpatient and outpatient treatment", Proc. XII Annual Meeting, Athens Greece, (19850900), vol. 3, no. Suppl. 1, pages 578 - 582, XP055307446
OPPOSITION- POUL STRANGE, "Treat-to-Target Insulin Titration Algorithms When Initiating Long or Intermediate Acting Insulin in Type 2 Diabetes", Journal of Diabetes Science and Technology, (20070700), vol. 1, no. Issue 4, XP055307441
OPPOSITION- JAY SKYLER et al., "Algorithms for Adjustment of Insulin Dosage by Patients Who Monitor Blood Glucose", Diabetes Care, (19810000), vol. 4, no. 2, doi:10.2337/diacare.4.2.311, pages 311 - 318, XP055307448
OPPOSITION- NAT PEMICK et al., "Personal Computer Programs to Assist with Self-Monitoring of Blood Glucose and Self-Adjustment - of Insulin Dosage", Diabetes Care, vol. 9, XP008179226

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents